Morgan Stanley Call 450 MDGL 20.1.../ DE000MG0D896 /
2024-05-16 5:47:42 PM | Chg.+0.090 | Bid10:00:36 PM | Ask10:00:36 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.480EUR | +23.08% | - Bid Size: - |
- Ask Size: - |
Madrigal Pharmaceuti... | 450.00 USD | 2024-12-20 | Call |
GlobeNewswire
05-07
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
04-23
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, ...
GlobeNewswire
04-16
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
04-09
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of...
GlobeNewswire
04-05
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for ...
GlobeNewswire
04-03
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-19
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire
03-14
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
GlobeNewswire
03-14
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Pati...
GlobeNewswire
03-06
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-05
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Res...
GlobeNewswire
02-28
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Fi...
GlobeNewswire
02-21
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
02-08
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in th...
GlobeNewswire
02-06
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
01-22
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
01-04
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG ...
GlobeNewswire
01-03
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-22
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-11-27
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)